Home Cart Sign in  
Chemical Structure| 2055397-28-7 Chemical Structure| 2055397-28-7

Structure of WM-1119
CAS No.: 2055397-28-7

Chemical Structure| 2055397-28-7

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

MOZ-IN-1 is an inhibitor of MOZ which is a member of histone acetyltransferases with IC50 of 0.051 μM.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of WM-1119

CAS No. :2055397-28-7
Formula : C18H13F2N3O3S
M.W : 389.38
SMILES Code : O=C(NNS(=O)(C1=CC=CC=C1F)=O)C2=CC(C3=NC=CC=C3)=CC(F)=C2
MDL No. :MFCD31690337
InChI Key :QLXULUNLCRKWRD-UHFFFAOYSA-N
Pubchem ID :133080719

Safety of WM-1119

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of WM-1119

epigenetics

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
ER-HOXA9 cells 4μM WM-1119 treatment significantly impaired the clonogenic potential of ER-HOXA9 cells. PMC8916037
GIST430 1 μM 42 days Inhibition of MOZ complex, reduced GIST cell proliferation PMC9453853
GIST-T1 0.1 μM 5 days Inhibition of MOZ complex, reduced GIST cell proliferation PMC9453853
MOZ-TIF2 LSK cells 3 nM to 10 μM 15 days To evaluate the effect of WM-1119 on the proliferation of MOZ-TIF2 LSK cells. Results showed a dose-dependent decrease in proliferation with an IC50 of 25 nM. PMC11214132
MT2 cells 0.1µM and 1µM every 2 days WM-1119 completely abrogated the proliferative and clonogenic potential of MT2 cells PMC11462755
PDLSCs 25 µM 24 hours Inhibition of KAT6A significantly reduced the expression and acetylation level of YAP, thereby affecting the RANKL/OPG ratio in PDLSCs. PMC11317454
RN2 cells 4μM 4 days WM-1119 treatment significantly increased surface expression of CD11b in RN2 cells, indicating induction of myeloid differentiation. PMC8916037
MOLM-13 cells 4μM 4 days To evaluate the effect of MI-3 on the viability of MLL-rearranged AML cells, showing that MI-3 significantly inhibited cell viability in a dose- and time-dependent manner. PMC8916037
UWB1.289-R cells 25 μm 72 hours Inhibited the catalytic function of KAT6A but had no effect on PARPi sensitivity PMC11425913
SKOV3-R cells 25 μm 72 hours Inhibited the catalytic function of KAT6A but had no effect on PARPi sensitivity PMC11425913

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice Subcutaneous xenograft model Intraperitoneal injection 3 mg/kg, 10 mg/kg, 30 mg/kg Once or twice daily for 14-28 days To evaluate the inhibitory effect of WM-1119 on the growth of SMARCB1-deficient tumors PMC11153594
C57BL/6 mice Orthodontic tooth movement model Periodontal injection 50 µg/kg Injected at 0, 2, 4, and 6 days, lasting for 7 days Inhibition of KAT6A significantly reduced the distance of tooth movement, decreased the number of TRAP-positive cells and RANKL-positive cells, and increased the number of OPG-positive cells. PMC11317454
Nude mice GIST-T1 cell line xenograft Oral gavage 50 mg/kg Three times daily for 28 days Inhibition of MOZ complex, significantly reduced tumor burden PMC9453853
Mice MOLM-13-luc cell transplantation model Tail vein injection Single injection, observed until endpoint KAT6A depletion significantly delayed leukemia progression and extended mouse survival. PMC8916037
Balb/c nude mice Subcutaneous xenograft model of SKOV3-R cells Intraperitoneal injection 60 mg/kg 2-4 times per week for 2-4 weeks Inhibited the catalytic function of KAT6A but had no effect on PARPi sensitivity PMC11425913

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.57mL

0.51mL

0.26mL

12.84mL

2.57mL

1.28mL

25.68mL

5.14mL

2.57mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories